A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
218 patients around the world
Available in Chile, United States
Bristol-Myers Squibb
218Patients around the world
This study is for people with
Solid tumors
Advanced tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Participants must have a life expectancy of at least 3 months at the time of the first dose.
Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
Participants must not have a history of serious recurrent infections.
Participants must not have a history of severe heart disease.
Other protocol-defined Inclusion/Exclusion criteria apply.
